ABSTRACT
Glymphatic function in animal models supports the clearance of brain proteins whose mis-aggregation is implicated in neurodegenerative conditions including Alzheimer’s and Parkinson’s disease. The measurement of glymphatic function in the human brain has been elusive, limiting its potential in translational research. Here we described a non-invasive multimodal device for the first-in-human continuous measurement of sleep-active glymphatic flow resistance using repeated electrical impedance spectroscopy measurements through two separate clinical validation studies. Device measurements successfully (i) paralleled sleep-associated changes in extracellular volume that regulate glymphatic function, (ii) replicated preclinical findings showing glymphatic function is increased with increasing sleep EEG delta power, and is decreased with increasing sleep EEG beta power and heart rate, and (iii) predicted glymphatic solute exchange measured by contrast-enhanced MRI. The present investigational device permits the continuous and time-resolved assessment of glymphatic flow resistance in naturalistic settings necessary to determine the contribution of glymphatic impairment to risk and progression of Alzheimer’s disease, and to enable target-engagement studies that modulate glymphatic function in humans.
Competing Interest Statement
The authors PD, LG, SRL, JW, TS, MML, JJI declare the existence of financial and incentive stock options competing interests. The authors YC and RMK declare the existence of financial competing interests.
Clinical Trial
NCT06060054, NCT06222385
Funding Statement
This study was funded by Applied Cognition.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
IRB of University of Florida gave ethical approval for this work (IRB No. 202201364) IRB of Western Institutional Review Board gave ethical approval for this work (IRB No. 20225818). The studies have been registered at ClinicalTrials.gov with identifier NCT06060054 and NCT06222385
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Revised Figures 3,4,5,6, added Supplemental Figure 1, added additional results to Tables 1,2, Supplemental Table 3, and updated Results and Discussion to reflect additional results.
Data availability
The data supporting the results in this study are available from the corresponding author with Institutional Review Board approval and Data Use Agreement permitting non-commercial use of data for independent validation, publication and sharing of new findings.
